Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. This growth was driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%.
The strong uptake of TONMYA underscores its market acceptance as the first new fibromyalgia treatment in over 15 years. The drug currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027, further broadening patient access.
Beyond commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, a condition with high unmet need. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives highlight the company's commitment to addressing significant CNS and immunology indications.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027, providing a solid runway to support its commercial and clinical activities.
The implications of these results are substantial. TONMYA's robust sales growth and expanding coverage indicate a strong commercial launch, positioning Tonix to capture a significant share of the fibromyalgia market. The progress in the pipeline, particularly the Phase 2 trials for MDD and Lyme disease prevention, could diversify the company's portfolio and create additional value. With a healthy cash position, Tonix is well-equipped to execute its strategic plans.
Investors and stakeholders will be watching closely as Tonix continues to execute on its commercial and clinical milestones. The company's ability to sustain TONMYA's momentum and advance its pipeline will be key to its long-term growth. For more details, the full press release is available at https://ibn.fm/6Yytj.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the company's flagship medicine. Tonix's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. The company is evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder. Additionally, its CNS portfolio includes TNX-2900 for Prader-Willi syndrome, and its immunology pipeline features TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention.
